Amid a global expansion push, SK bioscience has unveiled a growth strategy focused on broadening its reach in vaccine manufacturing and R&D. 

Going forward, the company plans to focus on responding to the endemic phase of the COVID-19 pandemic and expanding its vaccine business to a global market.

Further, the company will eye purchases of cell and gene therapy and next-generation platform technologies. Lastly, it´ll strengthen its global partnership, R&D and manufacturing capabilities to prepare for future pandemics and advance novel therapies, the company said.